MG
GNPX icon

Michael Gelband’s Genprex GNPX Stock Holding History

Michael Gelband’s Portfolio GNPX Stock Details GNPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Hold
0
– -$16K – 2359
2021
Q4 		– Hold
0
– – – 2089
2021
Q3 		– Sell
-1
Closed -$86K – 2312
2021
Q2 		$86K Buy
+1
New +$164K ﹤0.01% 2172

Other funds holding GNPX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Cypress Capital Franklin, Tennessee $370M AUM 16.36% 1-Year Est. Return

Michael Gelband's GNPX Position: Q1 2022 in Review

Michael Gelband held its Genprex (GNPX) position steady in Q1 2022 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2359.

Michael Gelband first reported a position in GNPX in Q2 2021 and has held it in 1 quarter since. The position peaked at $86K in Q2 2021. 20 funds tracked by Wall St. Rank hold GNPX as of Q1 2022.

  • Michael Gelband held 0 shares of Genprex worth $0 as of Q1 2022.
  • Michael Gelband left its Genprex share count unchanged in Q1 2022.
  • Genprex made up ﹤0.01% of Michael Gelband's portfolio in Q1 2022, its #2359 holding.
  • Michael Gelband first reported a position in Genprex in Q2 2021 and has held it in 1 quarter since.
  • Michael Gelband's Genprex position peaked at $86K in Q2 2021.
  • 20 funds tracked by Wall St. Rank held Genprex as of Q1 2022.

Based on ExodusPoint Capital Management's 13F filing for Q1 2022, filed 13 May 2022.